Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.35−0.18 (-5.10%)
Close on Nov 20, 2026Market cap $93.32MP/E –Yield –
Unicycive Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Unicycive Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $675.00K, down 29.0% year over year. For fiscal 2023 it was $675.00K, down 29.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $675.00K | -29.0% |
| FY2022 | Dec 31, 2022 | $951.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $675.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $951.00K | – |
See a number that looks wrong?